BIOMAT Database Logo BIOMAT Database Logo

Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease. 1996

M Boran, and I Dalva, and F Gönenç, and S Cetin

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002331 Carnitine A constituent of STRIATED MUSCLE and LIVER. It is an amino acid derivative and an essential cofactor for fatty acid metabolism. Bicarnesine,L-Carnitine,Levocarnitine,Vitamin BT,L Carnitine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias

Related Publications

M Boran, and I Dalva, and F Gönenç, and S Cetin
[Recombinant human erythropoietin (r-Hu-EPO) in the treatment of nephrogenic anemia].
November 1988, Polskie Archiwum Medycyny Wewnetrznej,
M Boran, and I Dalva, and F Gönenç, and S Cetin
The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
January 1991, Nephron,
M Boran, and I Dalva, and F Gönenç, and S Cetin
The effect of subcutaneous recombinant human erythropoietin (r-Hu EPO) in CAPD patients with renal anaemia.
January 1994, Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina,
M Boran, and I Dalva, and F Gönenç, and S Cetin
The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
August 1988, Behring Institute Mitteilungen,
M Boran, and I Dalva, and F Gönenç, and S Cetin
[Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
January 1999, Praxis,
M Boran, and I Dalva, and F Gönenç, and S Cetin
Recombinant human erythropoietin (r-hu-EPO) treatment in patients with rheumatoid arthritis and anaemia of chronic disease (ACD)
January 1994, Clinical and experimental rheumatology,
M Boran, and I Dalva, and F Gönenç, and S Cetin
Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
January 1989, Contributions to nephrology,
M Boran, and I Dalva, and F Gönenç, and S Cetin
Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease.
January 1989, Contributions to nephrology,
M Boran, and I Dalva, and F Gönenç, and S Cetin
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.
July 1987, The New England journal of medicine,
M Boran, and I Dalva, and F Gönenç, and S Cetin
Effect of recombinant human erythropoietin (r-Hu EPO) therapy on blood pressure in dialysis patients.
January 1994, Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina,
Copied contents to your clipboard!